FLT3 and acute myeloid leukemia: On July 20, 2023, the FDA approved the use of quizartinib with the standard 7 + 3 cytarabine and anthracycline induction, consolidation, and maintenance monotherapy following consolidation chemotherapy for FLT3-ITD-positive AML patients.